Seeking Druggable Targets in Progressive Fibrosing Interstitial Lung Disease or Pulmonary Hypertension

Johnson & Johnson, a global pharmaceutical company with cutting-edge capabilities in drug development and a history of successful academic collaborations, wishes to identify druggable targets in progressive fibrosing interstitial lung disease (PF‑ILD), idiopathic pulmonary fibrosis (IPF) and pulmonary hypertension (PH).

Research Interests

1. IPF/PF-ILDs

• Opportunities that offer the potential for clinical translation
• Mechanism of actions that reduce fibrosis by targeting TGF‑b signalling without the risk of inflammation, target activation, function of ...